If you have been reading about pentadecapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
==== Silver ==== A tarnished-silver or aluminium paint-like feces color characteristically results when biliary obstruction of any type (white stool) combines with gastrointestinal bleeding from any source (black stool). It can also suggest a carcinoma of the ampulla of Vater, which will result in gastrointestinal bleeding and biliary obstruction, resulting in silver stool.
Opioid rotation or opioid switching is the process of changing one opioid to another to improve pain control or reduce unwanted side effects. This technique was introduced in the 1990s to help manage severe chronic pain and improve the opioid response in cancer patients and non-cancer patients. In order to obtain adequate levels of pain relief, patients requiring chronic opioid therapy may require an increase in the original prescribed dose for a number of reasons, including increased pain or a worsening disease state. Over the course of long-term treatment, an increase in dosage cannot be continued indefinitely as unwanted side effects of treatment often become intolerable once a certain dose is reached, even though the pain may still not be properly managed. One strategy used to address this is to switch the patient between different opioid drugs over time, usually every few months. Opioid rotation requires strict monitoring in patients with ongoing levels of high opioid doses for extended periods of time, since long term opioid use can lead to a patient developing tolerance to the analgesic effects of the drug. Patients may also not respond to the first opioid prescribed to them at all, therefore needing to try another opioid to help manage their pain. A patient's specific response and sensitivity to opioids include many factors that include physiology, genetics and pharmacodynamic parameters, which together determine the amount of pain control and tolerance of a particular opioid.
== Remote monitoring and control == Modern refrigerated containers are often equipped with a telematic control unit and a GPS tracking unit that enables remote monitoring of the container's parameters as part of a fleet telematics system. This integration is part of the fleet digitalization of the logistics industry, making the container an element of a larger Vehicle tracking system. The system allows a fleet management operator to track the container's location and monitor internal parameters such as temperature, humidity, and door status. This continuous stream of telemetry provides a complete track and trace record of the container's temperature throughout its journey, which helps ensure the integrity of the cold chain. If the temperature deviates from the set point, the system can send an automatic alert to the operator, allowing for immediate intervention. These systems also allow for remote control, enabling an operator to change the temperature settings or turn the refrigeration unit on or off from a central software platform.
=== Utopia === Comparisons are often made between the Culture and twentieth and twenty-first century Western civilisation and nation-states, particularly their interventions in less-developed societies. These are often confused with regard to the author's assumed politics. Ben Collier has said that the Culture is a utopia carrying significantly greater moral legitimacy than the West's, by comparison, proto-democracies. While Culture interventions can seem similar at first to Western interventions, especially when considered with their democratising rhetoric, the argument is that the Culture operates completely without material need, and therefore without the possibility of baser motives. This is not to say that the Culture's motives are purely altruistic; a peaceful, enlightened universe full of good neighbours lacking ethnic, religious, and sexual chauvinisms is in the Culture's interest as well. Furthermore, the Culture's ideals, in many ways similar to those of the liberal perspective today, are to a much larger extent realised internally in comparison to the West.
Sources: en.wikipedia.org
== Production == StAR is a mitochondrial protein that is rapidly synthesized in response to stimulation of the cell to produce steroid. Hormones that stimulate its production depend on the cell type and include luteinizing hormone (LH), ACTH and angiotensin II. At the cellular level, StAR is synthesized typically in response to activation of the cAMP second messenger system, although other systems can be involved even independently of cAMP. StAR has thus far been found in all tissues that can produce steroids, including the adrenal cortex, the gonads, the brain and the nonhuman placenta. One known exception is the human placenta. Substances that suppress StAR activity, like those listed below, can cause endocrine disrupting effects, including altered steroid hormone levels and fertility.
=== Claude D. Pepper Older Americans Independence Center === The San Antonio Claude D. Pepper Older Americans Independence Center (OAIC) is one of only fifteen National Institute on Aging (NIA)-funded Pepper Centers in the United States. Established in 2015, the Center serves as the translational arm of the Barshop Institute's aging research enterprise, with the overarching goal of improving the health, physical function, and independence of older adults. In partnership with the South Texas Veterans Health Care System Geriatric Research, Education and Clinical Center (GRECC), the Center brings together basic scientists, clinician investigators, epidemiologists, and population scientists to translate discoveries in the biology of aging into interventions that preserve functional independence and improve quality of life. The San Antonio Pepper Center is nationally recognized as the first Claude D. Pepper Center organized around the principles of geroscience—the concept that aging itself is the primary biological risk factor underlying most chronic diseases and functional decline. Rather than studying age-related diseases in isolation, investigators focus on the fundamental mechanisms of aging that contribute to conditions such as frailty, sarcopenia, mobility impairment, cardiovascular disease, type 2 diabetes, Alzheimer's disease and related dementias, and other chronic disorders affecting older adults.
1905: American geneticist Nettie Stevens discovered sex chromosomes. 1906: Following the San Francisco earthquake, American botanist and curator Alice Eastwood rescued almost 1500 rare plant specimens from the burning California Academy of Sciences building. Her curation system of keeping type specimens separate from other collections – unconventional at the time – allowed her to quickly find and retrieve the specimens. 1906: Russian chemist Irma Goldberg published a paper on two newly discovered chemical reactions involving the presence of copper and the creation of a nitrogen-carbon bond to an aromatic halide. These reactions were subsequently named the Goldberg reaction and the Jourdan-Ullman-Goldberg reaction. 1906: English physicist, mathematician and engineer Hertha Ayrton became the first female recipient of the Hughes Medal from the Royal Society of London. She received the award for her experimental research on electric arcs and sand ripples. 1906: After her death, English lepidopterist Emma Hutchinson's collection of 20,000 butterflies and moths was donated to the London Natural History Museum. She had published little during her lifetime, and was barred from joining local scientific societies due to her gender, but was honoured for her work when a variant form of the comma butterfly was named hutchinsoni. 1907: Swedish-Norwegian physicist and nutritionist Signe Schmidt-Nielsen became one of the first women in Sweden to receive a doctoral degree. She was also the first woman to become a member of the Royal Norwegian Society of Sciences and Letters.
==== French Polynesia ==== In French Polynesia, glass noodles are known as vermicelle de soja and were introduced to the islands by Hakka agricultural workers during the 19th century. They are most often used in maʻa tinito, a dish made with glass noodles mixed together with pork, beans, and cooked vegetables.
=== Phase III - further modification and excretion === After phase II reactions, the xenobiotic conjugates may be further metabolised. A common example is the processing of glutathione conjugates to acetylcysteine (mercapturic acid) conjugates. Here, the γ-glutamate and glycine residues in the glutathione molecule are removed by Gamma-glutamyl transpeptidase and dipeptidases. In the final step, the cystine residue in the conjugate is acetylated. Conjugates and their metabolites can be excreted from cells in phase III of their metabolism, with the anionic groups acting as affinity tags for a variety of membrane transporters of the multidrug resistance protein (MRP) family. These proteins are members of the family of ATP-binding cassette transporters and can catalyse the ATP-dependent transport of a huge variety of hydrophobic anions, and thus act to remove phase II products to the extracellular medium, where they may be further metabolised or excreted.
Sources: en.wikipedia.org
== Further reading == Foreman, John C.; Johansen, Torben; Gibb, Alasdair J., eds. (2010). Textbook of Receptor Pharmacology. doi:10.1201/9781420052558. ISBN 978-0-429-14730-2. Brunton L (2011). Brunton LL, Chabner B, Knollmann BC (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12 ed.). New York: McGraw-Hill. ISBN 978-0-07-162442-8. Whalen K (2014). Lippincott Illustrated Reviews: Pharmacology.
== Sequence == The Kozak sequence was determined by sequencing of 699 vertebrate mRNAs and verified by site-directed mutagenesis. While initially limited to a subset of vertebrates (i.e. human, cow, cat, dog, chicken, guinea pig, hamster, mouse, pig, rabbit, sheep, and Xenopus), subsequent studies confirmed its conservation in higher eukaryotes generally. The sequence was defined as 5'-(gcc)gccRccAUGG-3' (IUPAC nucleobase notation summarized here) where:
=== Teflon (polytef) === This was the original material used as a bulking agent, first used to treat urinary incontinence in 1964, and then about 20 years later it was the first material used as a bulking agent to treat FI. Polytef paste is polytetrafluoroethylene, glycerin and polysorbide. The particles are mostly very small in size (4–40-μm). Research in animals has shown that these particles migrate and may be found in lymph nodes, lungs, kidneys, spleen and brain. If the material mostly migrates away, any benefit will be temporary, and there are safety concerns that it could lead to the formation of foreign body granulomas and the development of sarcoma.
== History == Before SHG was used for imaging, the first demonstration of SHG was performed in 1961 by P. A. Franken, G. Weinreich, C. W. Peters, and A. E. Hill at the University of Michigan, Ann Arbor using a quartz sample. In 1968, SHG from interfaces was discovered by Bloembergen and has since been used as a tool for characterizing surfaces and probing interface dynamics. In 1971, Fine and Hansen reported the first observation of SHG from biological tissue samples. In 1974, Robert W. Hellwarth and Christensen first reported the integration of SHG and microscopy by imaging SHG signals from polycrystalline ZnSe. In 1977, Colin Sheppard imaged various SHG crystals with a scanning optical microscope. The first biological imaging experiments were done by Freund and Deutsch in 1986 to study the orientation of collagen fibers in rat tail tendon. In 1993, Lewis examined the second-harmonic response of styryl dyes in electric fields. He also showed work on imaging live cells. In 2006, Goro Mizutani group developed a non-scanning SHG microscope that significantly shortens the time required for observation of large samples, even if the two-photons wide-field microscope was published in 1996 and could have been used to detect SHG. The non-scanning SHG microscope was used for observation of plant starch, megamolecule, spider silk and so on. In 2010 SHG was extended to whole-animal in vivo imaging. In 2019, SHG applications widened when it was applied to the use of selectively imaging agrochemicals directly on leaf surfaces to provide a way to evaluate the effectiveness of pesticides.
Apart from a detailed plotline and a few developers' screenshots, however, little information has been released about the game since 2005. Sparse updates have been published over the years at the company's official website and in a few specialized game magazines, and the final product is expected to be released via Steam. Drawing some comparisons to vaporware titles, Planet Half-Life announced (as a joke) on April 1, 2007 that They Hunger: Lost Souls had again been redesigned and was set for release as a Nintendo DS game. In November 2008, the developers of the Sven Co-op mod announced that they had been working with Black Widow Games to develop a co-op version of They Hunger, which was later released as an addon to be played in the mod in December 2008.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.